首页> 外文期刊>Reviews in Health Care >Appropriate administration of Granulocyte-Colony Stimulating Factors
【24h】

Appropriate administration of Granulocyte-Colony Stimulating Factors

机译:适当给予粒细胞集落刺激因子

获取原文
           

摘要

Chemotherapy-induced febrile neutropenia is a potentially fatal complication of cancer treatment and is also the main reason of dose-reduction and/or delay of chemotherapy regimen. Prophylaxis with G-CSF is applicable to reduce the risk of chemotherapy-induced neutropenia. Two molecules of recombinant G-CSF are available for clinical use: lenograstim, identical to human native G-CSF, that is derived from mammalian cells and filgrastim, different to human native G-CSF, expressed in E coli and commercialized in normal form and pegilated long-acting form. Neutrophil morphology and expected defense functions are modified by treatment with filgrastim, while they are not affected by lenograstim. These functionality differences observed in vitro are recently confirmed in a clinical trial that shows a lower incidence of febrile episodes with lenograstim compared to filgrastim in presence of G-CSF induced neutrophils. The long-term safety of lenograstim was supported by the results of a prospective, longer-term study involving almost 4,000 healthy donors. Another important question is the respect of timing of administration of G-CSF and chemotherapy. Absolutely in no case the plasma concentration of G-CSF is to be detected 48h before to 24h post chemotherapeutic drugs administration. In fact, this combination could result in an increased risk of mielotoxicity and a potential for an increase in sensitivity of rapidly dividing myeloid cells to cytotoxic-mutagenic chemotherapy potential. Lenograstim and filgrastim shows short half-life time, instead pegfilgrastim shows detectable concentrations for 16 days after a single administration. This is important to be considered, in particular in bi-weekly and tri-weekly adjuvant chemotherapy regimens. Anyway, the use of the lowest effective dose for the shortest adequate time of medications ensures the optimal balance among effectiveness, safety and costs of treatments, in a context that takes into account effectiveness and efficiency.
机译:化学疗法诱导的发热性中性粒细胞减少症是癌症治疗的潜在致命并发症,也是减少化疗方案剂量和/或延迟化疗的主要原因。 G-CSF预防可用于降低化疗引起的中性粒细胞减少症的风险。有两种重组G-CSF分子可用于临床使用:lenograstim,与人天然G-CSF相同,来源于哺乳动物细胞和filgrastim,不同于人天然G-CSF,在大肠杆菌中表达并以正常形式商业化, pe药的长效形式。中性粒细胞的形态和预期的防御功能可通过非格司亭治疗而得到改变,而不受雷诺格司亭的影响。最近在一项临床试验中证实了在体外观察到的这些功能差异,该试验显示,在存在G-CSF诱导的中性粒细胞的情况下,与非格司亭相比,来格司亭的高热发作的发生率更低。一项涉及近4,000名健康捐献者的前瞻性,长期研究的结果支持了来诺格司亭的长期安全性。另一个重要的问题是对G-CSF的给药时间和化疗的尊重。绝对不会在化疗药物给药前48小时至24小时后检测到G-CSF的血浆浓度。实际上,这种组合可能导致增加的细胞毒性风险和可能增加快速分裂的骨髓细胞对细胞毒性诱变化学疗法的敏感性。雷诺格司亭和非格司亭显示出短的半衰期,而pegfilgrastim单次给药后在16天内显示出可检测的浓度。重要的是要考虑到这一点,尤其是在每两周和每三周的辅助化疗方案中。无论如何,在考虑到有效性和效率的情况下,使用最短有效时间的最低有效剂量可确保有效性,安全性和治疗成本之间的最佳平衡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号